肾下型腹主动脉瘤腔内修复治疗的并发症分析

目的：总结腔内修复治疗腹主动脉瘤的经验,探讨并发症的及防治策略。方法：回顾分析及随访已接受腔内修复治疗的43例肾下型腹主动脉瘤患者的临床资料,分析腔内修复手术并发症的病因和防治。结果：本组发生了内漏、支架移位、移植物综合征、手术入路损伤等支架相关并发症。最常见的是内漏,发生原发性内漏11例,Ⅰ型8例,Ⅱ型1例,Ⅲ型2例。Ⅱ型内漏术中未处理,Ⅰ、Ⅲ型内漏经过球囊扩张、植入支架型血管或裸支架等处理后仍残留2例J型内漏。4例手术入路损伤经内膜剥脱治愈。随访发现迟发性内漏4例,继续随访1～2年,未见瘤体明显增大;手术结束时残留的3例原发性内漏自愈,但其中1例出现内漏复发及支架移位,导致动脉瘤复发破裂而再次接受腔内治疗。结论：支架相关并发症与动脉瘤血管解剖条件、移植物缺陷和操作技术有关,其防治需要良好把握手术适应证、合理选择支架及成熟的操作经验。     

复杂主动脉病变的腔内治疗和杂交手术

目的：总结复杂主动脉病变腔内治疗和杂交手术的疗效和近中期结果。方法：回顾性分析2003年4月—2012年12月间收治的53例复杂主动脉病变患者的临床资料，其中男39例，女14例；年龄31~82岁，平均55岁；主动脉夹层35例，主动脉弓动脉瘤2例，腹主动脉瘤16例；其中5例合并髂动脉瘤。分别采用不同的腔内技术和/或杂交手术治疗。结果：全组患者手术技术成功率100%。术中即刻发生I型内漏8例，2例在其近端加一Cuff后内漏消失，其他患者未作特殊处理。随访1~72个月，平均20.2个月，无移植物移位及器官缺血。随访患者中无I型内漏发生，发生II型内漏2例，未行特殊处理，后自愈；无截瘫病例；1例高龄腹主动脉瘤患者术后1个月死于痰堵塞导致的窒息。结论：腔内治疗和杂交手术治疗复杂主动脉病变具有较好的近、中期疗效，远期疗效有待进一步评估。

     

一体式覆膜支架在腹主动脉腔内修复中的应用

目的:总结一体式覆膜支架在腹主动脉以及髂动脉病变中的应用效果。方法:回顾性分析应用一体式腹主动脉覆膜支架腔内修复腹主动脉瘤15例、髂动脉瘤5例及腹主动脉或髂动脉夹层5例的临床资料。结果:平均时间42.4 min,手术成功率100%(25/25)。术后无I、III型内漏,发生髂动脉血栓形成1例,围术期无死亡病例。随访3~16个月复查无动脉瘤复发和II型内漏。结论:一体式覆膜支架是腹主动脉瘤和夹层动脉瘤腔内治疗方法的一种较好选择,具有快速、简单、有效的优点;其远期疗效需进一步观察。     

腹主动脉瘤腔内修复术中髂动脉瘤的处理策略

目的:探讨腹主动脉瘤合并髂动脉瘤的腔内修复术(EVAR)方法。方法:回顾性分析2007年8月—2014年3月35例腹主动脉瘤合并髂动脉瘤行EVAR术患者资料,其中9例合并单侧髂内动脉瘤,1例合并双侧髂内动脉瘤,14例合并单侧髂总动脉瘤(直径18 mm),11例合并双侧髂总动脉瘤,所用腔内技术包括栓塞髂内动脉瘤后覆盖,髂内动脉瘤单纯覆盖,"喇叭口"支架,以及"三明治"技术重建一侧髂内动脉等。结果:所有腔内技术均获得成功,手术时间(125±40)min,出血量(173±65)m L。术中发现内漏8例(22.9%),其中I型内漏4例(近端2例,远端2例)均经球囊扩张后内漏消失,III型内漏1例,经扩张及部分加弹簧圈栓塞后内漏消失,II型内漏2例及IV型内漏1例,均未予处理。35例术后随访6~60个月,无动脉瘤破裂,2例术后6个月发现腹主动脉瘤体增大,造影确诊远端I型内漏,经弹簧圈栓塞后内漏消失,其余33例瘤体直径无增大。结论:对于合并髂动脉瘤的腹主动脉瘤患者,有效处理髂内动脉,然后根据髂总动脉直径选择合适的治疗方法可以达到理想的近期效果。     

晚期妊娠和产褥期主动脉夹层的腔内修复治疗

目的：探讨腔内修复术治疗晚期妊娠和产褥期主动脉夹层的临床效果。方法：回顾性分析4例妊娠相关性B型主动脉夹层行腔内带膜支架修复术患者临床资料。在4例患者中，2例夹层发生于37孕周，1例发生于产后2 h，1例发生于产褥期；3例患马凡综合征（MFS），1例病因不明。患者均接受胸主动脉带膜支架腔内植入术，辅助技术包括主动脉狭窄段球囊扩张，左颈总动脉烟囱支架植入术。产妇及新生儿均进行临床观察随访，术后1，3，6个月分别对产妇进行CT血管造影监测。结果：围产期及随访时间无产妇及胎儿死亡，1例胎儿经阴道娩出，3例胎儿剖宫产娩出。4例患者主动脉支架均成功植入，初始破口完整覆盖，3例患者覆盖左锁骨下动脉，无I型内漏及支架移位。1例患者初始破口位于左锁骨下动脉开口处，锚定区向主动脉弓部拓展，同期植入左颈总动脉烟囱支架，术后出现II型内漏，随访11个月内漏自行消失。平均随访时间17.5个月，产后新生儿均存活良好，1例出现新生儿黄疸，产后12 d消失。结论：腔内带膜支架治疗晚期妊娠及产褥期B型主动脉夹层早-中期疗效肯定，手术时机与适应证需要根据孕产期临床状况综合判断。

     

合并双髂总动脉瘤的腹主动脉瘤的腔内治疗

目的总结腹主动脉瘤合并双髂总动脉瘤的腔内治疗经验。方法2009年1月～2012年3月,126例腹主动脉瘤接受腔内修复术（endovascularaneurysmrepair,EVAR）,其中33例合并双髂总动脉瘤（直径〉18mm）。27例双侧髂总动脉直径〉18-〈25mm,选择合适口径的髂腿移植物完成传统EVAR;6例因-侧髂总动脉直径≥25mm,选择该侧髂外动脉作为锚定区完成EVAR,并行髂内动脉栓塞术。结果所有腔内技术均获得成功,手术时间（115±36）min,出血量（173±65）m1。术中发现即刻内漏7例（21．2％）：I型内漏3例（近端1例,远端2例,均经球囊扩张后内漏消失）;11I型内漏1例,经扩张后内漏消失;II型内漏2例,Ⅳ型内漏1例,经随访瘤体直径未增大,未予处理。33例术后随访6～39个月,平均15．3月,无动脉瘤破裂,无远端迟发型I型内漏发生,髂动脉直径无明显扩张。结论对于部分合并双髂动脉瘤的腹主动脉瘤患者,根据髂总动脉直径选择合适的腔内治疗方法可以达到理想的治疗效果,近期效果满意。     

“烟囱”技术在Ⅲ型夹层动脉瘤和腹主动脉瘤腔内修复术中的应用

目的 总结“烟囱”技术在主动脉瘤腔内修复术中的应用体会和一期效果.方法 在30例主动脉瘤腔内修复术中使用“烟囱”技术增加近端覆膜支架锚定区,其中25例DebakeyⅢ型夹层动脉瘤使用“烟囱”支架保留左锁骨下动脉(23例)或左颈总动脉(3例),肾下腹主动脉瘤使用“烟囱”支架保留肾动脉(5例).结果 所有病例均顺利完成操作,放置“烟囱”支架的分支动脉术中造影均通畅.其中2例夹层动脉瘤(8％)和1例腹主动脉瘤残留(20％)少量Ⅰ型内漏,1例夹层动脉瘤左锁骨下动脉“烟囱”病例术后5d猝死,考虑为远侧破口所致夹层动脉瘤破裂.其余22例夹层动脉瘤和4例肾下腹主动脉瘤均无内漏.随访28例(90.3％),随访1～19个月,平均(6±5)个月.随访期超声或CTA示“烟囱”血管血流均通畅.1例腹主动脉瘤仍有内漏,2例夹层内漏病例随访中(尚未行CTA),其他病例瘤腔血栓形成.结论 “烟囱”技术能够有效的延长覆膜支架在主动脉瘤腔内修复术中的近端锚定区并保持重要分支动脉通畅.     

瘤颈捆扎治疗腹主动脉瘤腔内修复术后持续内漏的疗效分析

目的总结瘤颈捆扎治疗腹主动脉瘤腔内修复术后持续内漏的疗效。方法回顾性分析2019年6月至2022年4月北京大学人民医院10例行瘤颈捆扎手术患者的临床及随访资料。结果手术指征为术后持续Ⅰ型内漏6例、Ⅱ型内漏3例、存在内张力1例, 均合并动脉瘤增大或破裂。全麻下经腹入路套带控制肾下近端瘤颈后使用捆扎带进行加固。10例患者均获得手术成功, 无内漏残留, 无支架移植物闭塞。围手术期并发症包括1例伤口愈合延迟和1例不完全性肠梗阻, 无围手术期死亡。中位随访时间13个月, 未发现内漏复发。1例患者术后6个月因胸降主动脉瘤接受胸主动脉瘤腔内修复术;无其他主动脉相关二次手术或主动脉相关死亡。结论瘤颈捆扎治疗腹主动脉瘤腔内修复术后持续内漏相对微创, 可以有效消除内漏。     

高危复杂腹主动脉瘤腔内修复术临床分析

目的 评估应用多种腔内技术治疗高危复杂腹主动脉瘤的可行性.方法 2001年1月至2010年12月,共138例腹主动脉瘤患者接受腹主动脉腔内修复术(EVAR),其中9例患者为高危复杂性腹主动脉瘤.男性8例,女性1例,年龄26～87岁,平均67岁.其中2例近肾腹主动脉假性动脉瘤,5例近肾腹主动脉瘤,1例腹主动脉瘤合并双髂总动脉瘤及左侧髂内动脉瘤,1例EVAR术后右髂内动脉瘤.所采用的腔内技术包括:主动脉支架开窗技术和扇形技术2例,烟囱技术5例,球囊辅助下髂内动脉瘤腔内治疗1例和球囊辅助反转支架技术1例.结果 所有腔内技术均获得成功.术中支架释放后即刻发现内漏4例,其中1例患者为Ⅰ型和Ⅲ型内漏,经大动脉球囊扩张后内漏消失;2例Ⅰ型内漏,其中1例行弹簧栓栓塞成功,另1例行近端裸支架成功.1例Ⅱ型内漏,经随访瘤腔直径未增大,未处理.随访4～79个月,平均25.9个月.无动脉瘤破裂,动脉瘤瘤体直径均有不同程度的缩小.随访过程中7例患者的靶血管(肾动脉、肠系膜上动脉和髂内动脉)均保持通畅.1例髂内动脉重建支架术后18个月血栓形成,但无盆腔缺血等症状.结论 对于不能耐受手术的高危复杂腹主动脉瘤患者,选择合适的腔内技术可以增加EVAR术的成功率,近、中期效果满意.     

腹主动脉瘤腔内修复术中特殊远端锚定区的处理经验

目的探讨腹主动脉瘤腔内修复术中特殊远端锚定区的处理方法以及并发症。方法自1997年5月至2006年12月在150例包括髂总动脉瘤、髂内动脉瘤、髂动脉狭窄、严重成角等特殊远端锚定区的腹主动脉瘤腔内修复术中,根据情况选择不同的处理方式,术后观察内漏、缺血并发症、髂动脉瘤形态以及旁路血管的通畅性。结果围手术期死亡率4％（6／150）,总死亡率42．5％（51／120）。6例原发性远端I型内漏,5例自愈,1例转化为持续性内漏;3例髂内动脉返流引起的Ⅱ型内漏随访中均自愈。7例单臂支架型血管,股股旁路手术2年通畅率为86％;4例髂内动脉旁路手术2年通畅率为100％。11例栓塞单侧髂内动脉出现臀肌缺血症状,平均症状消失时间42 d（5-90 d）。结论结合传统外科技术以及腔内技术,并选择合适的产品处理腹主动脉瘤特殊远端锚定区可取得满意疗效。中远期结果仍需观察。     

Endoleak after endovascular repair of abdominal aortic aneurysm.

PURPOSE: We sought to assess the role of endovascular techniques in the management of perigraft flow (endoleak) after endovascular repair of an abdominal aortic aneurysm. METHOD: We performed endovascular repair of abdominal aortic aneurysm in 114 patients, using a variety of Gianturco Z-stent-based prostheses. Results were evaluated with contrast-enhanced computed tomography (CT) at 3 days, 3 months, 6 months, 12 months, and every year after the operation. An endoleak that occurred 3 days after operation led to repeat CT scanning at 2 weeks, followed by angiography and attempted endovascular treatment. RESULTS: Endoleak was seen on the first postoperative CT scan in 21 (18%) patients and was still present at 2 weeks in 14 (12%). On the basis of angiographic localization of the inflow, the endoleak was pure type I in 3 cases, pure type II in 9, and mixed-pattern in 2. Of the 5 type I endoleaks, 3 were proximal and 2 were distal. All five resolved after endovascular implantation of additional stent-grafts, stents, and embolization coils. Although inferior mesenteric artery embolization was successful in 6 of 7 cases and lumbar embolization was successful in 4 of 7, only 1 of 11 primary type II endoleaks was shown to be resolved on CT scanning. There were no type III or type IV endoleaks (through the stent-graft). Endoleak was associated with aneurysm dilation two cases. In both cases, the aneurysm diameter stabilized after coil embolization of the inferior mesenteric artery. There were two secondary (delayed) endoleaks; one type I and one type II. The secondary type I endoleak and the associated aneurysm rupture were treated by use of an additional stent-graft. The secondary type II endoleak was not treated. CONCLUSIONS: Type I endoleaks represent a persistent risk of aneurysm rupture and should be treated promptly by endovascular means. Type II leaks are less dangerous and more difficult to treat, but coil embolization of feeding arteries may be warranted when leakage is associated with aneurysm enlargement.     

腹主动脉瘤腔内治疗并发症内漏的诊治

目的 探讨血管内技术治疗腹主动脉瘤时特有并发症内漏的诊断与处理方法。方法 对已施行腔内治疗37例腹主动脉瘤患者进行回顾性分析,讨论部分患者并发内漏的原因、诊断、处理、结果及预后。结果 37例支架型血管放置完成后,13例发现存在不同程度的内漏,其中I型6例,Ⅱ型3例,Ⅲ型2例,Ⅳ型1例,不明原因1例,1期经相关技术处理后I型、Ⅲ型内漏完全消失。手术结束时原发性内漏发生率13．5％（5／37）。随诊发现原发性内漏3例自愈,2例转化为持续性内漏;另发现2例继发性内漏发生率13．5％（5／37）。随诊发现原发性内漏3例自愈,2例转化为持续性内漏;另发现2例继发发现人漏。本组患者晚期内漏发生率10．8％（4／37）。结论 引起漏血的原因可能与瘤颈形态、长度、成角、钙化、移植物选择、分支血管血液倒流等因素有关。强调术中发现并一期处理,术后应密切随访。增强CT、血管超声和MRA检查是术检后检测内漏的主要手段。对漏血量及瘤体有增大趋势的内漏应积极处理。     

Occult type I or III endoleaks are a common cause of failure of type II endoleak treatment after endovascular aortic repair

Objective

Most type II endoleaks have a benign natural history, but 6% to 8% are associated with sac enlargement and respond poorly to treatment. Our aim was to evaluate whether these enlargements are associated with delayed or occult type I and III endoleaks.

Fabric tears as a new cause of type III endoleak with Ancure endograft

PURPOSE: We present two case reports of type IIIb endoleak. One was due to fabric erosion caused by placement of a stent (Wallstent; W. L. Gore & Associates, Flagstaff, Ariz) after endovascular aneurysm repair; the other arose spontaneously. In both cases, an Ancure endograft (Guidant/EVT, Menlo Park, Calif) was placed. CASE REPORTS: In case 1, a large endoleak developed 36 months after uncomplicated endovascular treatment of an abdominal aortic aneurysm. In case 2, endoleak developed 30 months after a complicated procedure. In both cases, two Wallstents were used to treat type I endoleak and limb kinking in the first postoperative months. One type III endoleak was within the endograft at the level of the stents. CONCLUSION: To our knowledge, these are the first type III endoleaks reported in association with Ancure endografts. Placement of Wallstents inside endografts is of concern, and another indication for close monitoring during follow-up.     

What is the significance of endoleaks and endotension

Endovascular repair has been used over a decade as a treatment of abdominal aortic aneurysm, and has become a widely accepted treatment method with a low rate of perioperative complications. Endoleak, perigraft blood flow outside endograft but within aneurysmsac, has been intensively studied during the last 10 years of endovascular aneurysm repair (EVR). The natural history of aneurysms with endoleak and the true clinical significance of various types of endoleaks remains unclear. Type I/III endoleak has been found to be associated with aneurysm rupture, while the risk of rupture of aneurysms with type II endoleak and endotension appears very small. In endotension, the aneurysm sac remains pressurized, even if there is no evidence of an endoleak. Currently,it is accepted that type I/III endoleaks should be corrected, preferably by endovascular means, due to the risk of rupture. If endovascular repair is not possible, then open conversion should be considered. The risk of conversion should be weighed against the risk of aneurysm rupture. Treatment of type II endoleaks and endotension is more controversial. In those with aneurysm enlargement,secondary interventions are often performed.     

EVAR reintervention management strategies in contemporary practice

It is known that following an endovascular aneurysm repair (EVAR) procedure, patients may experience endoleaks, device migration, stent fractures, graft deterioration, or aneurysm growth that might require a reintervention. In this review management strategies of reinterventions after EVAR in contemporary practice will be discussed. The current endovascular treatment options of Type I endoleak involve securing of the attachment site with percutaneous transluminal balloon angioplasty, stent-graft extension, or placement of a stent at the proximal attachment site. Moreover, the use of endostaples to secure the position of the proximal cuff to the primary endograft have been developed. Type II endoleaks can be managed conservatively if the aneurysm is shrinking or remains stable. Otherwise, reinterventions include transarterial embolization, translumbar embolization, transcaval embolization, direct thrombin injection, and endoscopic or open ligation of the lumbar and mesenteric arteries. There is little debate regarding the treatment of type III endoleaks, including deployement of additional stent graft components to bridge the defect. Endovascular treatment of endotension includes endovascular conversion stent or relining of the stent graft. Alternative options are puncture of the aneurysm sac and removal of the aneurysm sac content. In case of migration large balloon-expandable stents can be used to improve the seal between the components, or devices that deploy staples to secure endovascular grafts to the aortic wall to secure endovascular components together. In conclusion, the first treatment options for reinterventions after EVAR are catheter based nowadays.